BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, has announced the pricing on March 7, 2023 of an underwritten public offering of 8,823,530 shares of its common stock at a public offering price of US$17.00 per share, before deducting underwriting discounts and commissions. In addition, BridgeBio has granted the underwriters a 30-day option to purchase up to an additional 1,323,529 shares of its common stock on the same terms and conditions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately US$150 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering to be sold by BridgeBio.
Latham & Watkins LLP represents the underwriters in the offering with a Bay Area capital markets team led by partners Shayne Kennedy and Phillip Stoup, with associates Casey Tong and Chelsi DeTurk, and Orange County associate Amy Lutfi. Advice was also provided on regulatory matters by Washington, D.C. partner Ben Haas and Bay Area partner Betty Pang, with Washington, D.C. associate Nathan Beaton and San Diego associate Keira Murphy; on IP matters by Bay Area partner Christopher Hazuka, with San Diego associates Rob Yeh and Kristina Funahashi; and on tax matters by Bay Area partner Grace Lee, with associate Alex Farris.
